Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Chu

Showing results (61-70 of 211) with videos related to

Pageof 22
Sort By:
Clinical Colorectal Cancer|April 12, 2008
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancerJames J Lee, Edward Chu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancerEdward Chu, Thomas H Cartwright
Oncology (Williston Park, N.Y.)|September 25, 2018
The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?James J Lee, Edward Chu
Cancer Journal (Sudbury, Mass.)|October 9, 2007
An update on treatment advances for the first-line therapy of metastatic colorectal cancerJames J Lee, Edward Chu
Clinical Colorectal Cancer|August 4, 2018
Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal CancerJames J Lee, Edward Chu
Cancer Journal (Sudbury, Mass.)|June 8, 2010
Biology of colorectal cancerMuhammad Wasif Saif, Edward Chu
Oncology (Williston Park, N.Y.)|May 2, 2012
Can metastatic colorectal cancer be cured?David L Bartlett, Edward Chu
Journal of Oncology Practice|April 12, 2017
Adjuvant Chemotherapy for Stage II Colon Cancer: The Debate Goes OnJames J Lee, Edward Chu
Clinical Colorectal Cancer|April 29, 2014
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancerJames J Lee, Edward Chu
Clinical Colorectal Cancer|December 6, 2007
First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancerJames J Lee, Edward Chu
Pageof 22

Showing results (61-70 of 211) with videos related to

Sort By:
Pageof 22
Clinical Colorectal Cancer|April 12, 2008
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancerJames J Lee, Edward Chu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancerEdward Chu, Thomas H Cartwright
Oncology (Williston Park, N.Y.)|September 25, 2018
The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More?James J Lee, Edward Chu
Cancer Journal (Sudbury, Mass.)|October 9, 2007
An update on treatment advances for the first-line therapy of metastatic colorectal cancerJames J Lee, Edward Chu
Clinical Colorectal Cancer|August 4, 2018
Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal CancerJames J Lee, Edward Chu
Cancer Journal (Sudbury, Mass.)|June 8, 2010
Biology of colorectal cancerMuhammad Wasif Saif, Edward Chu
Oncology (Williston Park, N.Y.)|May 2, 2012
Can metastatic colorectal cancer be cured?David L Bartlett, Edward Chu
Journal of Oncology Practice|April 12, 2017
Adjuvant Chemotherapy for Stage II Colon Cancer: The Debate Goes OnJames J Lee, Edward Chu
Clinical Colorectal Cancer|April 29, 2014
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancerJames J Lee, Edward Chu
Clinical Colorectal Cancer|December 6, 2007
First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancerJames J Lee, Edward Chu
Pageof 22